Swedish Orphan Biovitrum (Sobi) has started patient enrolment in the Phase III anaSTILLs clinical trial of Kineret (anakinra) for Still’s disease treatment.

Still’s disease is an auto-inflammatory disorder, while Kineret is an antagonist of interleukin-1 receptor and is indicated for minimising signs and symptoms of rheumatoid arthritis (RA).

The multi-centre, randomised, double-blind anaSTILLs trial will investigate the safety and efficacy of anakinra in newly diagnosed patients, including those with systemic juvenile idiopathic arthritis (SJIA) and adult onset Still’s disease (AOSD).

Sobi senior vice-president, chief medical officer and Research & Development head Milan Zdravkovic said: “We are very pleased with having initiated this confirmatory clinical study investigating the safety and efficacy of anakinra in people with Still’s disease.

"This is a disease affecting both young people and adults and is associated with a significant morbidity and with a large unmet medical need."

“This is a disease affecting both young people and adults and is associated with a significant morbidity and with a large unmet medical need.”

Set to be conducted in 81 subjects across North America, the Phase III trial is designed to compare two subcutaneous doses of anakinra with placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The firm has already initiated patient recruitment last month for the evaluation of Elocta (efmoroctocog alfa) in the ReITIrate trial to treat haemophilia A.

Being conducted in partnership with Bioverativ Therapeutics, the multi-centre, open-label trial will assess the immune tolerance induction (ITI) potential of Elocta in subjects with inhibitors that could not be resolved with other treatments.

Elocta is a recombinant clotting factor therapy engineered using Fc fusion technology to prolong circulation in the body.